PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 10, 2025Journal for ImmunoTherapy of CancerOpen Access

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMiguel B. GasparMNMarina NatoliLCLaure Castan

Discussion

Loading...

Member takes

Overview

Affinity-modulated T cell engager demonstrates potent anti-tumor activity in humanized mice, indicating safe cytokine profiles.

Key Points

  • AZD5863 exhibited significant tumor control across multiple cancer models, showing strong anti-tumor effects.
  • The T cell engager's potency was notably correlated with CLDN18.2 receptor density, optimizing therapeutic impact.
  • In vivo tests revealed lower cytokine release compared to T cell engagers with higher affinities for CD3, ensuring a safer profile.
  • This study informs future clinical trials, specifically a phase 1 trial targeting gastric and pancreatic adenocarcinoma.

Cite This Study

Gaspar et al. (2025) studied this question.

synapsesocial.com/papers/68c1b19354b1d3bfb60e8adchttps://doi.org/10.1136/jitc-2025-011857
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: Manifestation of a dual activation threshold2003 · 237 citations
  2. 2Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning2021 · 120 citations
  3. 3Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial2023 · 632 citations
  4. 4Claudins and alveolar epithelial barrier function in the lung2012 · 90 citations
  5. 5Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody2009 · 75 citations